



Key Figures – Eurofins Scientific Group

according to International Financial Reporting Standards (IFRS)


Operating profit in €Million




EBITDA in €Million



Sales in €Million



Average Number of Employees



Q1 = first quarter of the year

CAGR: Compound Annual Growth Rate

Company Profile

A global leader in bio-analysis

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing and advisory services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.

With more than 3,300 staff in more than 50 laboratories across 13 countries, Eurofins offers a portfolio of over 10,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our experts.

The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy to expand both its technology portfolio and its geographic reach. Through R&D, licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international player in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.

Shareholders' information in short

Listings

Euronext Paris (since IPO on 24.10.1997)
Frankfurter Wertpapierbörse/ XETRA Frankfurt (since SPO on 26.10.2000)

Segments/ Indexes

Paris: NextEconomy/ Next 150 & SBF 250
Frankfurt: Prime Standard/ Technology All Share

Industry Group/ Prime Sector

Biotechnology/ Pharma & Healthcare

Codes

ISIN: FR 0000038259
Paris: Euroclear 3825
Frankfurt: WKN 910251

Tickers

Paris: Reuters EUFI.LN, Bloomberg ERSC FP
Frankfurt: ESF, EUFI.DE

Nominal Capital (as of 31.03.2006)

1,377,255.60 € (13,772,556 x 0.10 €)

Simplified Ownership Structure (31.03.06)

51% Management incl. G. & Y.L. Martin
49% free float

International Investor Relations

Dr. Stefan Eckhoff
Eurofins Scientific Group
Phone: +32-2-766 16 20
E-mail: ir@eurofins.com

Investor Relations France

Hugues Vaussy
Eurofins Scientific S.A. (Nantes)
Phone: +33-2-51 83 21 00
E-mail: irFrance@eurofins.com

Internet

www.eurofins.com

Disclaimer

THIS REPORT MAY CONTAIN FORWARD-LOOKING STATEMENTS AND ESTIMATES THAT INVOLVE RISKS AND UNCERTAINTIES. THE FORWARD-LOOKING STATEMENTS AND ESTIMATES CONTAINED HEREIN REPRESENT THE JUDGEMENT OF EUROFINS SCIENTIFIC AS OF THE DATE OF THIS RELEASE. THESE FORWARD-LOOKING STATEMENTS ARE NOT GUARANTEES FOR FUTURE PERFORMANCE, AND THE FORWARD-LOOKING

EVENTS DISCUSSED IN THIS REPORT MAY NOT OCCUR. EUROFINS SCIENTIFIC DISCLAIMS ANY INTENT OR OBLIGATION TO UPDATE ANY OF THESE FORWARD-LOOKING STATEMENTS AND ESTIMATES. ALL STATEMENTS AND ESTIMATES ARE MADE BASED ON THE DATA AVAILABLE TO THE COMPANY AS OF THE DATE OF PUBLICATION, BUT NO GUARANTEE CAN BE MADE AS TO THEIR VALIDITY.

Operating and Financial Review and Prospects

Financial figures in this report were prepared based on the International Financial Reporting Standards (IFRS). All accounts are consolidated at the Eurofins Scientific Group level. The Company's auditors have conducted a limited review on these accounts.

Dear Shareholders,

Eurofins started the year 2006 with a very good quarter. Sales increased by 56% to €70.1 million. Growth was significant throughout the regions where the Group is active due to strong organic growth, acquisitions and outsourcing agreements.

In spite of the fact that the first quarter is traditionally the weakest of the year, operating profit was up almost 87% to reach €5.1 million (€2.7 million in Q1/ 2005). Net profit for the period increased by 96% to €2.3 million in Q1/ 2006 (€1.2 million in Q1/ 2005). Earnings per share in the first quarter amounted to €0.14 compared with €0.08 in Q1/ 2005.

At 7.3% the operating profit margin was more than 1%-point higher than in Q1/ 2005. Both sales and margins are above expectations in Q1/ 2006 but do not modify Eurofins' objectives for 2006. The Group's focus is not to maximise short-term operating margins but its main financial goal is to create long-term value for shareholders by deploying increasing amounts of capital at high levels of ROCE.

Eurofins' first OBSAR bond issue was very well received. The €119.2 million raised allowed the Group to review its existing lines of credit and led to the repayment of €46.6 million of amounts borrowed. As a result, the liquid funds increased by 265% to €101.3 million at the end of Q1/ 2006 compared with the previous year (€27.8 million).

During the first three months of 2006, Eurofins acquired several new laboratories. They include Pharmacontrol (Colmar/ France), Optimed (Grenoble/ France), GAB Biotechnologie (Pforzheim/ Germany) and Agrisearch (East Midlands/ UK). These acquisitions together with the strong organic growth achieved in Q1/ 2006 confirm that the Group's objective to reach a turnover of €300 million in 2006 appears realistic.

I am looking forward to another successful year for Eurofins in 2006 and I would like to thank all our clients, employees and shareholders who participate in this progress.

Sincerely,




Dr. Gilles G. Martin
CEO

Operating Revenues

In the first quarter of 2006, Eurofins reached sales of €70.1 million representing a growth of 56% compared with Q1/ 2005 (€44.9 million).

The increase in revenues resulted from a strong organic growth as well as from acquisitions and outsourcing agreements, which were carried out during the past 12 months and have been consolidated in Q1/ 2006. Particularly in France, Germany and the USA, the growth was reinforced by the first full consolidation of companies such as LEM, GAB Biotechnologie and AvTech.

Breakdown of sales by region for Q1/ 2006 as % of sales:



€million	Q1/2006	%	Q1/2005	%
Benelux	8.1	11.5	7.4	16.5
British Isles	5.2	7.4	3.7	8.4
France	15.5	22.1	8.4	18.8
Germany	17.1	24.3	6.4	18.9
North America	11.0	15.6	6.9	14.3
Scandinavia	9.0	12.9	8.5	15.3
Other	4.4	6.2	3.5	7.8
Total	70.1	100.0	44.9	100.0

Net Income

In the first quarter of 2006, EBITDA grew by 63% to €9.0 million (€5.6 million in Q1/ 2005). In the same period, operating profit improved by almost 87% to reach €5.1 million (€2.7 million in Q1/ 2005). This corresponds to an operating profit margin of 7.3% of sales (6.1% in Q1/ 2005).

Net profit for the period increased by 96% to €2.3 million in Q1/ 2006 (€1.2 million in Q1/ 2005). Earnings per share in the first quarter amounted to €0.14 compared with €0.08 in Q1/ 2005.

Cash Flow and Liquidity

Net cash provided by operating activities in Q1/ 2006 amounted to €5.7 million (€-0.6 million in Q1/ 2005) mainly due to the increase of net profit, of depreciation and to a lower change in net working capital.

Purchase of property, plant and equipment and of intangible assets (CAPEX) amounted to €6.3 million in Q1/ 2006 and decreased as a percentage of sales from 10.2% in Q1/ 2005 to 9.0% in Q1/ 2006.

Eurofins' first OBSAR bond issue was very well received. The €119.2 million raised allowed the Group to review its existing lines of credit and led to the repayment of €46.6 million of amounts borrowed. As a result, the liquid funds increased by 265% to €101.3 million at the end of Q1/ 2006 compared with the previous year (€27.8 million).

Balance Sheet

The significant increase of the balance sheet sum to €374.6 million in Q1/ 2006 (€266.2 million at the end of 2005) is mainly due to the OBSAR bond (€118.4 million impact on balance sheet), which caused an increase of the cash position from €41.2 million at the end of 2005 to €104.6 million in Q1/ 2006. Furthermore, the increase reflects the overall growth of the Group's activities linked to the investing activities into new laboratories and participations and their subsequent consolidation.

The increase of net financial debt to €74.5 million (€60.2 million at the end of 2005) represents the corresponding financing needs for the acquisitions, the investments into the business and the working capital.

OBSAR Bond Issue

In Q1/ 2006, an issue of OBSAR (bonds with redeemable warrants) was successfully carried out with subscription rights (DPS) for the existing shareholders. The nominal amount of this issue amounted to €120 million.

In the past, Eurofins financed its growth with a combination of equity (last issue in October 2000) and bilateral and syndicated bank loans. The present OBSAR issue makes it possible to consolidate the bank financing over a longer period (average maturity 6 years). As the amount raised exceeds its short-term needs, Eurofins reviews the use of its existing lines of credit.

This emission should contribute as well to reduce Eurofins' weighted average cost of capital (WACC), which is one of the objectives sought by complementing equity financing with debt.

Strategic Acquisitions and Geographic Expansion

During the first quarter of 2006, several excellent businesses have joined the pharmaceutical division of the Eurofins Group. They include:

- Pharmacontrol (Colmar/ France)
- Optimed (Grenoble/ France)
- GAB Biotechnologie (Pforzheim/ Germany)
- Agrisearch (East Midlands/ UK)

With other sites in Scandinavia, Germany and Switzerland, the portfolio offered by the Eurofins Pharmaceutical Services Division now spans almost all the product development cycle. These acquisitions take Eurofins Pharmaceutical Services Division one step closer to its objective of becoming a one-stop global full service provider for product development. Very few companies offer such a broad technical and geographic portfolio. Eurofins Pharmaceutical Services is rapidly expanding its activities in North America and has now become one of the largest European contract research organisations (CROs). The Group focuses on being the most recognised, high quality development services provider of choice to the pharmaceutical, biotechnology and crop protection industries.

Sales and Marketing

In Q1/ 2006, Eurofins has implemented new, fast methods of extraction and automated clean-up steps that revolutionise the turn-around times of dioxin analyses. Results can now be obtained on request after 24 – 36 hours instead of several weeks. With the newly opened state-of-the-art laboratory in Hamburg, one of the most modern laboratories in Europe, Eurofins has increased its analytical capac-

ity to over 1,500 dioxin samples per month in this facility alone. This enormous capability is unique in the world and is ensured by 10 high-resolution GC/MS systems. Sufficient resources are especially important in crisis situations in order to be in a position to guarantee fast turn-around-times even then.

As of mid-March, the test kit for soil and groundwater, TerrAttesT, offered by the Group's environmental division in the Netherlands has been fully accredited on ISO 17025.

Another accreditation was achieved by the certification business in France. This includes maintaining the accreditation to certify for IFR standard delivered by COFRAC as well as the initial accreditation to certify according to the British Retail Consortium (BRC, global food) standard, the two main relevant standards for food safety worldwide.

Employees

The overall average weighted number of employees (3,368) has increased by 47% in comparison with Q1/ 2005 (2,294). This increase is due to several acquisitions made within the past 12 months.

As of	31.03.2006	31.03.2005
Benelux	554	520
France	789	462
Germany	965	501
North America	304	241
Scandinavia	394	311
British Isles	318	225
Other	45	34
Total	3,368	2,294

Employee numbers are weighted average "Full time equivalents" (FTE) over the period, i.e. the figures are weighted by the time that (acquired) laboratories are fully consolidated in the Group.

The overall personnel costs for the Eurofins Scientific staff including social security and pension costs amounted to €34.5 million or 49.3% as percentage of sales in Q1/ 2006 (51.1% in Q1/ 2005).

Directors Holdings

The summary as of March 31, 2006 is listed below:

As of 31.03.2006	No. of Shares	No. of Stock Options
Gilles G. Martin	4,258,840	0
Svend Aage Linde	197,741	29,000
Valérie Hanote	107,170	0
Wicher R. Wichers	71,546	44,000
Yves-Loïc Martin	22,600	0

Analytical Bioventures SCA, which is controlled by Gilles and Yves-Loïc Martin, holds 2,220,000 shares.

Consolidated Financial Statements

Consolidated Profit and Loss Statement

January 1, 2006 to March 31, 2006
(after limited review)

€ Thousand	Q1/ 2006	Q1/ 2005
Revenues	70,137	44,880
Cost of purchased materials and services	-28,400	-16,754
Personnel expenses	-34,544	-22,941
Other operating income and expenses, net	1,852	376
EBITDA	9,044	5,561
Depreciation and amortisation	-3,937	-2,825
Operating profit	5,108	2,736
Finance costs	-973	-770
Share of (loss)/ profit of associates	-7	-8
Result before income taxes	4,128	1,957
Income tax expense	-1,815	-776
Net profit for the period	2,313	1,181
Attributable to:		
Minority interest	417	72
Equity holders of the Company	1,896	1,109
Earnings per share (basic) in €	0.14	0.08
Earnings per share (diluted) in €	0.13	0.08
Weighted average shares outstanding (basic)	13,754	13,625
Weighted average shares outstanding (diluted)	14,537	14,375

Consolidated Balance Sheet

As of March 31, 2006
(after limited review)

€ Thousand	31.03.2006	31.12.2005
Property, plant and equipment	52,817	46,589
Intangible assets	4,397	4,055
Goodwill	108,761	89,345
Investments in associates	9,567	720
Financial assets	7,889	6,714
Derivative financial instruments	75	75
Deferred tax asset	3,111	2,773
Total non current assets	186,618	150,271
Inventories	14,087	9,430
Trade accounts receivable	57,535	56,543
Prepaid expenses and other current assets	11,225	7,653
Corporate tax receivable	462	1,025
Cash and cash equivalents	104,634	41,240
Total current assets	187,941	115,891
Total assets	374,559	266,162
Share capital	1,377	1,375
Other reserves	58,582	58,385
Retained earnings	23,519	20,996
Exchange differences	-1,477	-1,182
Shareholders' equity – part of the group	82,001	79,574
Minority interest	3,666	2,842
Total shareholders' equity	85,667	82,416
Borrowings	41,719	72,146
OBSAR Bonds	118,383	0
Derivative financial instruments	138	296
Pension accrual	3,040	2,877
Account payable on investment	19,734	6,342
Provisions for other liabilities and charges	10,628	11,119
Deferred tax liability	768	964
Total non current liabilities	194,411	93,744
Borrowings	19,069	29,327
Trade accounts payable	24,572	23,676
Advance payments received and deferred revenues	8,059	3,790
Corporate tax due	6,295	5,121
Account payable on investment	8,518	2,620
Other current liabilities	27,968	25,468
Total current liabilities	94,481	90,002
Total liabilities and shareholders' equity	374,559	266,162

Consolidated Cash Flow Statement

January 1, 2006 to March 31 2006
(after limited review)

€ Thousand	Q1/ 2006	Q1/ 2005
Cash flows from operating activities		
Result before income taxes	4,128	1,957
Adjustments for:		
Depreciation and amortisation	3,937	2,836
Increase/ decrease in provisions and accruals	-1,175	-572
Losses/ gains on the disposal of fixed assets	0	-23
Share-based payments and options	87	59
Financial income and expense, net	1,101	659
Expense/ income from investments (equity method)	7	8
Derivative financial instruments – income statement	-158	184
Change in net working capital	-949	-3,913
Cash generated from operations	6,978	1,196
Interest received	534	93
Interest paid	-1,069	-746
Income taxes paid	-734	-1,154
Net cash provided by operating activities	5,709	-611
Cash flows from investing activities		
Acquisitions of subsidiaries, net of cash acquired	-7,493	-9,386
Proceeds from disposal of a subsidiary, net of cash transferred	0	0
Purchase of property, plant and equipment	-5,889	-4,465
Purchase of intangible assets	-437	-115
Proceeds from sale of property, plant and equipment	36	50
Purchase net of sales of investments and financial assets	-5,277	-5,248
Net cash used in investing activities	-19,060	-19,164
Cash flows from financing activities		
Proceeds from issuance of share capital	199	11
Proceeds from short or long term borrowings	6,621	17,270
Cash repayments of amounts borrowed	-46,623	-2,203
OBSAR Bonds	119,201	0
Purchase net of sales of treasury shares	0	0
Dividends to minority interest	0	0
Net cash provided by financing activities	79,398	15,078
Net effect of currency translation in cash and cash equivalents	-56	81
Net increase (decrease) in liquid funds	65,990	-4,616
Liquid funds at beginning of period	35,357	32,422
Liquid funds * at end of period	101,347	27,806

* Liquid funds + overdraft = cash and cash equivalents

Consolidated Statement of Changes in Equity

As of March 31, 2006
(after limited review)

€Thousand	Shareholder's equity part of the group				Minority Interest	Total equity
	Share capital	Other reserves	Retained earnings	Exchange Differences		
Balance at January 1, 2005	1,363	57,585	8,996	-2,091	246	66,098
Currency translation differences	0	0	-1	910	-14	895
Financial instruments	0	0	-497	0	-74	-571
Share based payments	0	0	241	0	0	241
Work in progress	0	0	-135	0	0	-135
Net profit	0	0	12,392	0	1,426	13,818
Total recognised income for 2005	0	0	12,000	910	1,338	14,248
Treasury stock	0	0	0	0	0	0
Issue of share capital	13	800	0	0	0	813
Dividends to minority interest	0	0	0	0	-3	-3
Minority interest arising on business combinations	0	0	0	0	1,260	1,260
Balance at December 31, 2005	1,375	58,385	20,996	-1,182	2,842	82,416
Currency translation differences	0	0	2	-296	-19	-313
Financial instruments	0	0	0	0	0	0
Share based payments	0	0	87	0	0	87
BSAR Bonds issued	0	0	537	0	0	537
Net profit	0	0	1,896	0	417	2,313
Total recognised income for 2006	0	0	2,523	-296	398	2,625
Treasury stock	0	0	0	0	0	0
Issue of share capital	2	197	0	0	0	199
Dividends to minority interest	0	0	0	0	0	0
Minority interest arising on business combinations	0	0	0	0	428	428
Balance at March 31, 2006	1,377	58,582	23,519	-1,477	3,666	85,667

The total number of ordinary shares is 13,773 million shares with a par value of € 0.10 per share. All issued shares are fully paid.

During the first quarter of 2006, the share capital increased by 25,000 new shares by exercise of employee stock options. As at 31st March 2006, the Company did not own any of its own shares (number of own shares at December 31, 2005: 0).

Interim Notes

General

We inform you that these Interim Notes are summarised. Some elements of the notes are included in the Quarterly Management Report:

- Material transactions and events of the current interim period.
- Revenues split by geographical segments.

1. Accounting policies

The accounting policies adopted in the preparation of these consolidated financial statements are described in the Annual Report 2005.

The consolidated financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union.

This interim report complies with IAS 34 (Interim Financial Reporting).

2. Change in the scope 2006

Company *	Country	Status	% of control	% of ownership	Consolidation method	Date of entry
		<i>Subsidiary of:</i>				
GAB Biotechnologies GmbH	Germany	Eurofins Ventures BV	100	100	Full consolidation	01/06
GAB Analytik GmbH	Germany	Eurofins Ventures BV	100	100	Full consolidation	01/06
AUA GmbH and its subsidiaries	Germany	Eurofins Umwelt GmbH	100	100	Full consolidation	01/06
Lucon GmbH	Germany	Eurofins Umwelt GmbH	100	100	Full consolidation	01/06
U-Lab GmbH	Germany	Analytis GmbH	100	60.61	Full consolidation	01/06
LBE SAS	France	Eurofins Ventures BV	100	100	Full consolidation	01/06
Pharmacontrol SAS	France	Eurofins Ventures BV	100	100	Full consolidation	01/06
Optimed SA	France	Eurofins Ventures BV	100	77.60	Full consolidation	01/06
Eurofins C Mark BV	Netherlands	Analytico Food BV	100	100	Full consolidation	03/06

* Please note that for confidentiality reasons the information provided is not comprehensive.

The company Agriseach Ltd and its subsidiaries were purchased in the first quarter 2006. They will be included in the consolidation as of the second quarter 2006.

3. Contingencies

The contingencies are described in more detail in the Annual Report 2005 in the Note 4.2.

The liabilities/ borrowings listed below are already included in the Group's balance sheet. The following table only repeats these amounts when these borrowings are secured by covenants or securities on assets.

€ Thousand	31/03/2006	31/12/2005
Bank borrowings secured over buildings and assets	32,034	63,227
Leases secured over buildings and assets *	5,411	5,060
Bank borrowings secured by covenants	13,547	26,019
OBSAR Bonds secured by covenants	118,383	0
Total	169,375	94,306

As at March 31st, 2006, the cash and cash equivalents reach € 104,634 K.

* Lease liabilities are effectively secured as the rights to the leased asset revert to the lessor in the event of default.

Detail of specific contingencies linked to acquisitions:

Rights to acquire or sell additional shares of three companies have been signed at a formula price already fixed to be exercised during the period 2007-2011. The contingencies linked to the right to acquire or sell shares in these companies (not yet booked in the consolidated balance sheet) are estimated to an amount of € 9.1 million.

4. Stock option plans

Stock options are granted to directors and employees. Movements in the number of share options outstanding are as follows (amounts in thousands):

At beginning of the year	701
Options granted	100
Options exercised	-25
Options expired	0
At end of the period	776

5. Post closing events

None.

6. Exceptional events during the interim period

None.

PricewaterhouseCoopers Entreprises
34, place Viarme
BP 90928
44009 Nantes Cedex 1

Tel +33 (0)2 51 84 36 36
Fax +33 (0)2 51 84 06 22

HLP Audit
4, rue Amédée Ménard
BP 32532
44325 Nantes Cedex 3

Tel +33 (0)2 40 37 00 34
Fax +33 (0)2 40 37 00 44

**Statutory Auditor's Report on the Consolidated Financial Statements
for the period ended March 31, 2006 prepared in accordance with the IFRS
as adopted in the EU**

Translated from French to English

This version of the report is a translation from the original, which was prepared in French. In all matters of interpretation of information, views or opinions expressed therein, the original language version of the report takes precedence over this translation.

To the Board of Directors of
Eurofins Scientific S.A.
Rue Pierre Adolphe Bobierre

44323 – Nantes Cedex 3

Dear Sirs,

At your request and as statutory auditor of your company, we have reviewed the accompanying consolidated balance sheet of Eurofins Scientific SA Company at March 31, 2006, and the related statements of income and cash flows for the period then ended.

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with professional standards applicable in France. Those standards require that we plan and perform the review to obtain moderate assurance as to whether the consolidated financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements are not prepared, in all material respects, in accordance with the IFRS as adopted by the European Union.

Nantes, France,

May 12, 2006


Auditors

**PricewaterhouseCoopers Entreprises
Member of PricewaterhouseCoopers**



**Yves Pelle
Partner**

HLP Audit



**Jacques le Pomellec
Partner**